Global Pancreatic Cancer Drugs Report Thumbnail

Global Pancreatic Cancer Drugs Market by Type (Drugs Approved for Pancreatic Cancer, Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation), Afinitor (Everolimus), Erlotinib Hydrochloride, Everolimus, 5-FU (Fluorouracil Injection), Fluorouracil Injection, Gemcitabine Hydrochloride, Other), By Application (Hospitals, Clinics) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028

  • Report ID: PH-566
  • Author: Up Market Research
  • Rating: 4.8
  • Total Reviews: 60
  • No. Of Pages: 247
  • Format:
  • Pub. Date: 2021-03-01
  • Share:

The global pancreatic cancer drugs market is expected to grow from USD 1,619.5 million in 2018 to USD 2,824.7 million by 2028 at a compound annual growth rate (CAGR) of 8.4% during the forecast period from 2018-2028.

Pancreatic cancer drugs are substances that may be used to treat pancreatic cancer. The type of treatment a person receives depends on the stage and type of pancreatic cancer they have, as well as their age and general health. There is no cure for pancreatic cancer, so treatments focus on slowing down its growth until it can be eliminated or cured by surgery.

On the basis of type, the global pancreatic cancer drugs market is segmented into Drugs Approved for Pancreatic Cancer, Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation), Afinitor (Everolimus), Erlotinib Hydrochloride, Everolimus, Fluorouracil Injection, Gemcitabine Hydrochloride.

Drugs Approved For Pancreatic Cancer

The drugs approved for pancreatic cancer include Abraxane (Paclitaxel Albumin-Stabilized Nanoparticle Formulation), Afinitor (Everolimus), Erlotinib Hydrochloride, Everolimus, and Gemcitabine Hydrochloride. These come in the form of tablets or injections, depending on the drug.

Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation)

Abraxane is a type of drug approved for pancreatic cancer treatment. It's also known as Paclitaxel Albumin-stabilized Nanoparticle Formulation, which has some advantages over traditional chemotherapy drugs. Abraxane consists of nanoparticles that are stabilized by albumin to help them attach and stay inside the tumor cells longer than other types of chemotherapy medications. This helps stop metastasis (cancer spreading from one organ or area in the body). Pancreatic Cancer Treatment with Abraxane - How Does it Work? Patients receive an infusion intravenously once per week for up to six weeks followed by another cycle every three months until they can no longer tolerate their side effects because this medication could damage organs like your kidneys if used too long.

Afinitor (Everolimus)

Afinitor (Everolimus) is a cancer treatment medication. It works by blocking the action of certain proteins that can cause uncontrolled cell growth in some types of cancer cells. Afinitor and similar medications are called tyrosine kinase inhibitors, or TKIs for short. This type of medicine helps to prevent new blood vessel formation required for tumor growth and kills rapidly dividing abnormal blood cells as well as other fast-growing cancers such as myeloma, leukemia, lymphomas, sarcomas, and plasmacytoma. Afinitor is used to treat various types of cancer, including kidney cancer.

Erlotinib Hydrochloride

Erlotinib Hydrochloride is used to treat pancreatic cancer. It belongs to a group of medicines called tyrosine kinase inhibitors (TKIs). Erlotinib Hydrochloride blocks the action of certain substances in the body that promote cancer. This slows down the growth of cancer cells.

Erlotinib Hydrochloride is used to treat pancreatic cancer that has not been treated before or spread outside the pancreas (usually advanced stages). It may also be used as a second-line treatment after gemcitabine-based therapy and, in some cases, chemotherapy when tumors cannot be removed by surgery.

Everolimus

Everolimus, also known by its trade name Afinitor®, is a drug in the class of immunosuppressants. The FDA approved it for use as adjuvant therapy to prevent recurrence after surgery (abdominal and pancreatic cancer) or radiotherapy for hepatocellular carcinoma. It binds to an intracellular protein called mTOR that controls cell growth. By binding, Everolimus inhibits the activity of this protein which halts tumor expansion across different organ systems. Furthermore, it can be used in combination with other medications such as Erlotinib Hydrochloride and Gemcitabine Hydrochloride.

Fluorouracil Injection

Fluorouracil Injection is a chemotherapy drug that interferes with the growth of cancer cells. It belongs to a group of medicines called "antimetabolites." Fluorouracil works by interfering with DNA replication and cell division. When it enters normal body cells, fluorouracil acid leaves them unable to divide or reproduce themselves normally. This may stop cancer from growing so quickly (in some cases). In addition, when used as an antineoplastic agent in specific situations such as treatment for breast tumors that have spread outside the breast before they can be surgically removed, fluoro-uracil medication has been found effective because it slows down tumor progression. Fluorouracil is also used to prevent the spread of tumors in people with cancer that has been removed by surgery.

Gemcitabine Hydrochloride

Gemcitabine hydrochloride is an anti-cancer drug of the gemcitabine family. It was developed by Eli Lilly and Company in 1974 as a chemotherapy agent for human pancreatic cancer and has since been used to treat other cancers. Gemcitabine hydrochloride belongs to the class of drugs called nucleosides which act on DNA synthesis in cells during cell division (mitosis). Like all cytotoxic agents, it also affects normal tissues that are rapidly dividing such as hair follicles and bone marrow.

On the basis of application, the global pancreatic cancer drugs market is segmented into Hospitals, Clinics.

Hospitals

the application in hospitals is focused on the treatment of pancreatic cancer. Hospitals use gemcitabine hydrochloride to kill dividing cells that are responsible for cancerous growths or tumors. This drug, like other anti-cancer drugs, works by interfering with cell division and replication which can be caused due to faulty DNA material being copied from a parent chromosome into new chromosomes (chromosomes). Cancer occurs when there is an uncontrolled and abnormal rate of multiplication of these damaged cells.

Clinics

Clinics use pancreatic cancer drugs to help patients with the disease. The type of drug varies depending on what stage it is, but chemotherapy like Gemcitabine and Fluorouracil are given as a first-line response for this treatment option. When prescribed intravenously or injected into the abdomen, these medications can be administered in cycles that last from six weeks up to eight months.

On the basis of region, the global pancreatic cancer drugs market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

North America accounted for the largest market share of global pancreatic cancer drugs. In 2017, it was followed by Europe and the Asia Pacific respectively due to the increasing rate of obesity in these regions.

The future estimates indicate that North America will continue to dominate until 2024 because of a growing elderly population and high prevalence rates among people above 50 years old who are at risk from this disease.

Asia-Pacific region is expected to witness significant growth owing to an increased demand for anti-cancer therapies amid rising health awareness across emerging countries such as India, China, South Korea, etc., which majorly contribute towards the total revenue generated through sales of drugs used for treating pancreatic cancer like Afinitor (Everolimus). Oncologists and physicians in the Asia-Pacific region are increasingly adopting modern treatment methods and novel therapies for pancreatic cancer, which is also expected to drive demand over the next ten years.

Middle East country like Saudi Arabia has emerged as a hot spot for pancreatic cancer drugs market owing to its rapidly rising population and increasing adoption of western lifestyle which will significantly contribute towards the growth of this region during the forecast period from 2019-2028.

Growth Factors

The growth factors for the global pancreatic drugs market include introduction and approval process approvals for new drugs such as Afinitor (Everolimus), Erlotinib Hydrochloride, Everolimus, and Gemcitabine Hydrochloride in recent years. The growth factors also include the introduction of newer drugs such as Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation).

The global pancreatic cancer market is driven by the number of new cases diagnosed with this disease each year. In 2017, globally there were around 225000 new cases reported. As more people are getting diagnosed with this ailment every year it has led to a spike in demand for treatment options which has further fueled the drug market growth. This high incidence rate is expected to increase from now until 2030 when experts predict that about 290000 new diagnoses will be made annually worldwide.


Up Market Research published a new report titled “Pancreatic Cancer Drugs Market research report which is segmented by Types (Drugs Approved for Pancreatic Cancer, Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation), Afinitor (Everolimus), Erlotinib Hydrochloride, Everolimus, 5-FU (Fluorouracil Injection), Fluorouracil Injection, Gemcitabine Hydrochloride, Other), By Applications (Hospitals, Clinics), By Players/Companies Eli Lilly and Company, Celgene, Roche, Novartis, Clovis Oncology, Amgen, Merck, Teva Pharmaceutical Industries, Pfizer, PharmaCyte Biotech”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.

 

Report Scope

Report Attributes Report Details
Report Title Pancreatic Cancer Drugs Market Research Report
By Type Drugs Approved for Pancreatic Cancer, Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation), Afinitor (Everolimus), Erlotinib Hydrochloride, Everolimus, 5-FU (Fluorouracil Injection), Fluorouracil Injection, Gemcitabine Hydrochloride, Other
By Application Hospitals, Clinics
By Companies Eli Lilly and Company, Celgene, Roche, Novartis, Clovis Oncology, Amgen, Merck, Teva Pharmaceutical Industries, Pfizer, PharmaCyte Biotech
Regions Covered North America, Europe, APAC, Latin America, MEA
Base Year 2020
Historical Year 2018 to 2019 (Data from 2010 can be provided as per availability)
Forecast Year 2028
Number of Pages 247
Number of Tables & Figures 173
Customization Available Yes, the report can be customized as per your need.
 

The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.


Global Pancreatic Cancer Drugs Industry Outlook
 

Global Pancreatic Cancer Drugs Market Report Segments:

The market is segmented by Type Drugs Approved for Pancreatic Cancer, Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation), Afinitor (Everolimus), Erlotinib Hydrochloride, Everolimus, 5-FU (Fluorouracil Injection), Fluorouracil Injection, Gemcitabine Hydrochloride, Other and By Application Hospitals, Clinics.

 

Some of the companies that are profiled in this report are:

  1. Eli Lilly and Company
  2. Celgene
  3. Roche
  4. Novartis
  5. Clovis Oncology
  6. Amgen
  7. Merck
  8. Teva Pharmaceutical Industries
  9. Pfizer
  10. PharmaCyte Biotech
 

Pancreatic Cancer Drugs Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.

 

Key Benefits for Industry Participants & Stakeholders:

  • Industry drivers, restraints, and opportunities covered in the study
  • Neutral perspective on the market performance
  • Recent industry trends and developments
  • Competitive landscape & strategies of key players
  • Potential & niche segments and regions exhibiting promising growth covered
  • Historical, current, and projected market size, in terms of value
  • In-depth analysis of the Pancreatic Cancer Drugs Market
 

Overview of the regional outlook of the Pancreatic Cancer Drugs Market:

Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.


Pancreatic Cancer Drugs Market Overview
 

Highlights of The Pancreatic Cancer Drugs Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of Pancreatic Cancer Drugs Market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2028.
  5. Developments and trends in the market.
  6. By Type:

                1. Drugs Approved for Pancreatic Cancer

                2. Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation)

                3. Afinitor (Everolimus)

                4. Erlotinib Hydrochloride

                5. Everolimus

                6. 5-FU (Fluorouracil Injection)

                7. Fluorouracil Injection

                8. Gemcitabine Hydrochloride

                9. Other

       7. By Application:

                1. Hospitals

                2. Clinics

  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.
 

We have studied the Pancreatic Cancer Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.

 

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Pancreatic Cancer Drugs Market Statistics
 

Reasons to Purchase the Pancreatic Cancer Drugs Market Report:

  • The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
  • Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
  • Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
  • The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
  • Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Pancreatic Cancer Drugs Market Overview
   4.1 Introduction 
      4.1.1 Market Taxonomy 
      4.1.2 Market Definition 
      4.1.3 Macro-Economic Factors Impacting the Market Growth 
   4.2 Pancreatic Cancer Drugs Market Dynamics 
      4.2.1 Market Drivers 
      4.2.2 Market Restraints 
      4.2.3 Market Opportunity 
   4.3 Pancreatic Cancer Drugs Market - Supply Chain Analysis 
      4.3.1 List of Key Suppliers 
      4.3.2 List of Key Distributors 
      4.3.3 List of Key Consumers 
   4.4 Key Forces Shaping the Pancreatic Cancer Drugs Market 
      4.4.1 Bargaining Power of Suppliers 
      4.4.2 Bargaining Power of Buyers 
      4.4.3 Threat of Substitution 
      4.4.4 Threat of New Entrants 
      4.4.5 Competitive Rivalry 
   4.5 Global Pancreatic Cancer Drugs Market Size & Forecast, 2018-2028 
      4.5.1 Pancreatic Cancer Drugs Market Size and Y-o-Y Growth 
      4.5.2 Pancreatic Cancer Drugs Market Absolute $ Opportunity 


Chapter 5 Global Pancreatic Cancer Drugs Market Analysis and Forecast by Type
   5.1 Introduction
      5.1.1 Key Market Trends & Growth Opportunities by Type
      5.1.2 Basis Point Share (BPS) Analysis by Type
      5.1.3 Absolute $ Opportunity Assessment by Type
   5.2 Pancreatic Cancer Drugs Market Size Forecast by Type
      5.2.1 Drugs Approved for Pancreatic Cancer
      5.2.2 Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation)
      5.2.3 Afinitor (Everolimus)
      5.2.4 Erlotinib Hydrochloride
      5.2.5 Everolimus
      5.2.6 5-FU (Fluorouracil Injection)
      5.2.7 Fluorouracil Injection
      5.2.8 Gemcitabine Hydrochloride
      5.2.9 Other
   5.3 Market Attractiveness Analysis by Type

Chapter 6 Global Pancreatic Cancer Drugs Market Analysis and Forecast by Applications
   6.1 Introduction
      6.1.1 Key Market Trends & Growth Opportunities by Applications
      6.1.2 Basis Point Share (BPS) Analysis by Applications
      6.1.3 Absolute $ Opportunity Assessment by Applications
   6.2 Pancreatic Cancer Drugs Market Size Forecast by Applications
      6.2.1 Hospitals
      6.2.2 Clinics
   6.3 Market Attractiveness Analysis by Applications

Chapter 7 Global Pancreatic Cancer Drugs Market Analysis and Forecast by Region
   7.1 Introduction
      7.1.1 Key Market Trends & Growth Opportunities by Region
      7.1.2 Basis Point Share (BPS) Analysis by Region
      7.1.3 Absolute $ Opportunity Assessment by Region
   7.2 Pancreatic Cancer Drugs Market Size Forecast by Region
      7.2.1 North America
      7.2.2 Europe
      7.2.3 Asia Pacific
      7.2.4 Latin America
      7.2.5 Middle East & Africa (MEA)
   7.3 Market Attractiveness Analysis by Region

Chapter 8 Coronavirus Disease (COVID-19) Impact 
   8.1 Introduction 
   8.2 Current & Future Impact Analysis 
   8.3 Economic Impact Analysis 
   8.4 Government Policies 
   8.5 Investment Scenario

Chapter 9 North America Pancreatic Cancer Drugs Analysis and Forecast
   9.1 Introduction
   9.2 North America Pancreatic Cancer Drugs Market Size Forecast by Country
      9.2.1 U.S.
      9.2.2 Canada
   9.3 Basis Point Share (BPS) Analysis by Country
   9.4 Absolute $ Opportunity Assessment by Country
   9.5 Market Attractiveness Analysis by Country
   9.6 North America Pancreatic Cancer Drugs Market Size Forecast by Type
      9.6.1 Drugs Approved for Pancreatic Cancer
      9.6.2 Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation)
      9.6.3 Afinitor (Everolimus)
      9.6.4 Erlotinib Hydrochloride
      9.6.5 Everolimus
      9.6.6 5-FU (Fluorouracil Injection)
      9.6.7 Fluorouracil Injection
      9.6.8 Gemcitabine Hydrochloride
      9.6.9 Other
   9.7 Basis Point Share (BPS) Analysis by Type 
   9.8 Absolute $ Opportunity Assessment by Type 
   9.9 Market Attractiveness Analysis by Type
   9.10 North America Pancreatic Cancer Drugs Market Size Forecast by Applications
      9.10.1 Hospitals
      9.10.2 Clinics
   9.11 Basis Point Share (BPS) Analysis by Applications 
   9.12 Absolute $ Opportunity Assessment by Applications 
   9.13 Market Attractiveness Analysis by Applications

Chapter 10 Europe Pancreatic Cancer Drugs Analysis and Forecast
   10.1 Introduction
   10.2 Europe Pancreatic Cancer Drugs Market Size Forecast by Country
      10.2.1 Germany
      10.2.2 France
      10.2.3 Italy
      10.2.4 U.K.
      10.2.5 Spain
      10.2.6 Russia
      10.2.7 Rest of Europe
   10.3 Basis Point Share (BPS) Analysis by Country
   10.4 Absolute $ Opportunity Assessment by Country
   10.5 Market Attractiveness Analysis by Country
   10.6 Europe Pancreatic Cancer Drugs Market Size Forecast by Type
      10.6.1 Drugs Approved for Pancreatic Cancer
      10.6.2 Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation)
      10.6.3 Afinitor (Everolimus)
      10.6.4 Erlotinib Hydrochloride
      10.6.5 Everolimus
      10.6.6 5-FU (Fluorouracil Injection)
      10.6.7 Fluorouracil Injection
      10.6.8 Gemcitabine Hydrochloride
      10.6.9 Other
   10.7 Basis Point Share (BPS) Analysis by Type 
   10.8 Absolute $ Opportunity Assessment by Type 
   10.9 Market Attractiveness Analysis by Type
   10.10 Europe Pancreatic Cancer Drugs Market Size Forecast by Applications
      10.10.1 Hospitals
      10.10.2 Clinics
   10.11 Basis Point Share (BPS) Analysis by Applications 
   10.12 Absolute $ Opportunity Assessment by Applications 
   10.13 Market Attractiveness Analysis by Applications

Chapter 11 Asia Pacific Pancreatic Cancer Drugs Analysis and Forecast
   11.1 Introduction
   11.2 Asia Pacific Pancreatic Cancer Drugs Market Size Forecast by Country
      11.2.1 China
      11.2.2 Japan
      11.2.3 South Korea
      11.2.4 India
      11.2.5 Australia
      11.2.6 South East Asia (SEA)
      11.2.7 Rest of Asia Pacific (APAC)
   11.3 Basis Point Share (BPS) Analysis by Country
   11.4 Absolute $ Opportunity Assessment by Country
   11.5 Market Attractiveness Analysis by Country
   11.6 Asia Pacific Pancreatic Cancer Drugs Market Size Forecast by Type
      11.6.1 Drugs Approved for Pancreatic Cancer
      11.6.2 Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation)
      11.6.3 Afinitor (Everolimus)
      11.6.4 Erlotinib Hydrochloride
      11.6.5 Everolimus
      11.6.6 5-FU (Fluorouracil Injection)
      11.6.7 Fluorouracil Injection
      11.6.8 Gemcitabine Hydrochloride
      11.6.9 Other
   11.7 Basis Point Share (BPS) Analysis by Type 
   11.8 Absolute $ Opportunity Assessment by Type 
   11.9 Market Attractiveness Analysis by Type
   11.10 Asia Pacific Pancreatic Cancer Drugs Market Size Forecast by Applications
      11.10.1 Hospitals
      11.10.2 Clinics
   11.11 Basis Point Share (BPS) Analysis by Applications 
   11.12 Absolute $ Opportunity Assessment by Applications 
   11.13 Market Attractiveness Analysis by Applications

Chapter 12 Latin America Pancreatic Cancer Drugs Analysis and Forecast
   12.1 Introduction
   12.2 Latin America Pancreatic Cancer Drugs Market Size Forecast by Country
      12.2.1 Brazil
      12.2.2 Mexico
      12.2.3 Rest of Latin America (LATAM)
   12.3 Basis Point Share (BPS) Analysis by Country
   12.4 Absolute $ Opportunity Assessment by Country
   12.5 Market Attractiveness Analysis by Country
   12.6 Latin America Pancreatic Cancer Drugs Market Size Forecast by Type
      12.6.1 Drugs Approved for Pancreatic Cancer
      12.6.2 Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation)
      12.6.3 Afinitor (Everolimus)
      12.6.4 Erlotinib Hydrochloride
      12.6.5 Everolimus
      12.6.6 5-FU (Fluorouracil Injection)
      12.6.7 Fluorouracil Injection
      12.6.8 Gemcitabine Hydrochloride
      12.6.9 Other
   12.7 Basis Point Share (BPS) Analysis by Type 
   12.8 Absolute $ Opportunity Assessment by Type 
   12.9 Market Attractiveness Analysis by Type
   12.10 Latin America Pancreatic Cancer Drugs Market Size Forecast by Applications
      12.10.1 Hospitals
      12.10.2 Clinics
   12.11 Basis Point Share (BPS) Analysis by Applications 
   12.12 Absolute $ Opportunity Assessment by Applications 
   12.13 Market Attractiveness Analysis by Applications

Chapter 13 Middle East & Africa (MEA) Pancreatic Cancer Drugs Analysis and Forecast
   13.1 Introduction
   13.2 Middle East & Africa (MEA) Pancreatic Cancer Drugs Market Size Forecast by Country
      13.2.1 Saudi Arabia
      13.2.2 South Africa
      13.2.3 UAE
      13.2.4 Rest of Middle East & Africa (MEA)
   13.3 Basis Point Share (BPS) Analysis by Country
   13.4 Absolute $ Opportunity Assessment by Country
   13.5 Market Attractiveness Analysis by Country
   13.6 Middle East & Africa (MEA) Pancreatic Cancer Drugs Market Size Forecast by Type
      13.6.1 Drugs Approved for Pancreatic Cancer
      13.6.2 Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation)
      13.6.3 Afinitor (Everolimus)
      13.6.4 Erlotinib Hydrochloride
      13.6.5 Everolimus
      13.6.6 5-FU (Fluorouracil Injection)
      13.6.7 Fluorouracil Injection
      13.6.8 Gemcitabine Hydrochloride
      13.6.9 Other
   13.7 Basis Point Share (BPS) Analysis by Type 
   13.8 Absolute $ Opportunity Assessment by Type 
   13.9 Market Attractiveness Analysis by Type
   13.10 Middle East & Africa (MEA) Pancreatic Cancer Drugs Market Size Forecast by Applications
      13.10.1 Hospitals
      13.10.2 Clinics
   13.11 Basis Point Share (BPS) Analysis by Applications 
   13.12 Absolute $ Opportunity Assessment by Applications 
   13.13 Market Attractiveness Analysis by Applications

Chapter 14 Competition Landscape 
   14.1 Pancreatic Cancer Drugs Market: Competitive Dashboard
   14.2 Global Pancreatic Cancer Drugs Market: Market Share Analysis, 2019
   14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.3.1 Eli Lilly and Company
      14.3.2 Celgene
      14.3.3 Roche
      14.3.4 Novartis
      14.3.5 Clovis Oncology
      14.3.6 Amgen
      14.3.7 Merck
      14.3.8 Teva Pharmaceutical Industries
      14.3.9 Pfizer
      14.3.10 PharmaCyte Biotech
Segments Covered in the Report
The global Pancreatic Cancer Drugs market has been segmented based on

By Types
  • Drugs Approved for Pancreatic Cancer
  • Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation)
  • Afinitor (Everolimus)
  • Erlotinib Hydrochloride
  • Everolimus
  • 5-FU (Fluorouracil Injection)
  • Fluorouracil Injection
  • Gemcitabine Hydrochloride
  • Other
By Applications
  • Hospitals
  • Clinics
Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • Eli Lilly and Company
  • Celgene
  • Roche
  • Novartis
  • Clovis Oncology
  • Amgen
  • Merck
  • Teva Pharmaceutical Industries
  • Pfizer
  • PharmaCyte Biotech

Buy Report